Clinical Trials Browser

Suspensions × Clear all

NCT03756311 2026-01-23

Expanded Access to NanoPac

No longer available

GenitourinaryThoracic

Lung Neoplasms, Prostatic Neoplasms

NCT04060628 2026-01-23

Expanded Access to NanoDoce

No longer available

Urogenital Neoplasms

NCT04544995 2026-01-21

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Phase 1 Terminated

47 enrolled 43 charts

Neoplasms, Neuroblastoma, Osteosarcoma

NCT04898543 2025-12-11

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1/2 Recruiting

CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

NCT04314895 2025-05-23

Trial of NanoPac Intratumoral Injection in Lung Cancer

Phase 2 Completed

18 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Phase 1 Terminated

3 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

NCT06597916 2024-11-27

RSV Vaccination in Immunocompromised Patients.

Phase 2 Recruiting

Respiratory Syncytial Virus Infections

NCT04727138 2022-05-16

3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546

Phase 1 Completed

Neoplasms

NCT04221828 2022-03-29

Trial of NanoPac Focal Therapy for Prostate Cancer

Phase 2 Terminated

1 enrolled 5 charts

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT04771390 2021-08-25

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

Phase 1 Completed

Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

NCT04260360 2020-08-04

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

Phase 1 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01697020 2013-12-02

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Phase 1 Completed

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma